Director/PDMR Shareholding | 12-Jun-2024 | 15:30 | RNS |
Statement: Zantac (ranitidine) litigation | 11-Jun-2024 | 07:00 | RNS |
Statement: Zantac (ranitidine) litigation | 10-Jun-2024 | 18:27 | RNS |
FDA approves Arexvy for adults 50-59 at risk | 10-Jun-2024 | 07:00 | RNS |
Total Voting Rights | 03-Jun-2024 | 15:00 | RNS |
Unprecedented results in Jemperli trial continue | 03-Jun-2024 | 13:03 | RNS |
ASCO positive Blenrep DREAMM-8 trial results | 03-Jun-2024 | 07:05 | RNS |
Statement: Zantac (ranitidine) litigation | 03-Jun-2024 | 07:00 | RNS |
Statement: Zantac (ranitidine) litigation | 24-May-2024 | 07:00 | RNS |
Positive phase III asthma results for depemokimab | 21-May-2024 | 07:00 | RNS |
Director/PDMR Shareholding | 20-May-2024 | 15:30 | RNS |
GSK completes sale of shares in Haleon plc | 17-May-2024 | 07:00 | RNS |
GSK announces intention to sell shares in Haleon | 16-May-2024 | 16:42 | RNS |
Director/PDMR Shareholding | 14-May-2024 | 15:30 | RNS |
Block listing Interim Review | 13-May-2024 | 15:00 | RNS |
Currency | UK Pounds |
Share Price | 1,604.50p |
Change Today | -5.50p |
% Change | -0.34 % |
52 Week High | 1,812.50p |
52 Week Low | 1,316.00p |
Volume | 4,229,876 |
Shares Issued | 4,144.96m |
Market Cap | £66,506m |
RiskGrade | 129 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 8 |
Buy | 4 |
Neutral | 10 |
Sell | 2 |
Strong Sell | 0 |
Total | 24 |
Latest | Previous | |
---|---|---|
Q1 | Q4 | |
Ex-Div | 16-May-24 | 22-Feb-24 |
Paid | 11-Jul-24 | 11-Apr-24 |
Amount | 15.00p | 16.00p |
Time | Volume / Share Price |
16:35 | 35,372 @ 1,604.50p |
16:35 | 2,548 @ 1,604.50p |
16:35 | 2,217,428 @ 1,604.50p |
16:35 | 2,192 @ 1,604.50p |
16:35 | 1,750 @ 1,604.50p |
You are here: research